Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Is the Neutrophil-Lymphocyte Ratio an Indicator of Progression in Patients with Benign Prostatic Hyperplasia?

  • Tanik, Serhat (Department of Urology, Bozok University, School of Medicine) ;
  • Albayrak, Sebahattin (Department of Urology, Bozok University, School of Medicine) ;
  • Zengin, Kursad (Department of Urology, Bozok University, School of Medicine) ;
  • Borekci, Hasan (Department of General Surgery, Bozok University, School of Medicine) ;
  • Bakirtas, Hasan (Department of Urology, Bozok University, School of Medicine) ;
  • Imamoglu, M. Abdurrahim (Department of Urology, Bozok University, School of Medicine) ;
  • Gurdal, Mesut (Department of Urology, Bozok University, School of Medicine)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The aim of this study was to evaluate inflammation parameters and assess the utility of the neutrophil-lymphocyte ratio (NLR) as a simple and readily available predictor for clinical disease activity in patients with nenign prostate hyperplasia BPH. We also aimed to investigate the relationship between inflammatory parameters with ${\alpha}$-blocker therapy response, and evaluate the potential association between NLR and the progression of benign prostatic hyperplasia (BPH). Materials and Methods: We examined 320 consecutive patients (July 2013-December 2013) admitted to our outpatient clinic with symptoms of the lower urinary tract at Bozok University. The mean age was 60 (range, 51-75) years. Complete blood count (CBC), prostate-specific antigen (PSA), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were assessed. Correlations between PSA, CRP, ESR, prostate volume, International Prostate Symptom Score (IPPS), maximum urinary flow rate (Qmax), and NLR were assessed statistically. Patients were divided into two groups: high and low risk of progression. Results: NLR was positively correlated with IPSS (p=0.001, r=0.265), PSA (p=0.001, r=0.194), and negatively correlated with Qmax (p<0.001, r=-0.236). High-risk patients a had a higher NLR compared with low-risk patients, based on IPSS (p<0.001), PSA (p=0.013), and Qmax (p<0.001); however, there were no significant differences between the groups in terms of age (p>0.05), and prostate volume (p>0.05). Conclusions: NLR can predict BPH progression. We propose that increased inflammation is negatively associated with clinical status in BPH patients and suggest that NLR can give information along with LUTS severity which may be used as a readikly accessible marker for patient follow-up.

Keywords

References

  1. Araki T, Monden K, Araki M (2013). Comparison of 7 alpha(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study. Acta Med Okayama, 67, 245-51.
  2. Celikbilek M, Dogan S, Ozbakir O, et al (2013). Neutrophillymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal, 27, 72-6. https://doi.org/10.1002/jcla.21564
  3. Cihan YB, Arslan A, Ergul MA (2013). Subtypes of white blood cells in patients with prostate cancer or benign prostatic hyperplasia and healthy individuals. Asian Pac J Cancer Prev, 14, 4779-83. https://doi.org/10.7314/APJCP.2013.14.8.4779
  4. Crawford ED, Wilson SS, McConnell JD, et al (2006). Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol, 175, 1422-6; discussion 6-7. https://doi.org/10.1016/S0022-5347(05)00708-1
  5. De Marzo AM, Platz EA, Sutcliffe S, et al (2007). Inflammation in prostate carcinogenesis. Nat Rev Cancer, 7, 256-69. https://doi.org/10.1038/nrc2090
  6. De Nunzio C, Kramer G, Marberger M, et al (2011). The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol, 60, 106-17. https://doi.org/10.1016/j.eururo.2011.03.055
  7. Di Silverio F, Gentile V, De Matteis A, et al (2003). Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol, 43, 164-75. https://doi.org/10.1016/S0302-2838(02)00548-1
  8. Djavan B, Eckersberger E, Espinosa G, et al (2009). Complex mechanisms in prostatic inflammatory response. Eur Urology Supplements, 8, 872-8. https://doi.org/10.1016/j.eursup.2009.11.003
  9. Emberton M, Fitzpatrick JM, Rees J (2011). Risk stratification for benign prostatic hyperplasia (BPH) treatment. BJU Int, 107, 876-80. https://doi.org/10.1111/j.1464-410X.2010.10041.x
  10. Falahatkar S, Mokhtari G, Pourreza F, et al (2008). Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology, 72, 813-6. https://doi.org/10.1016/j.urology.2008.04.069
  11. Fibbi B, Penna G, Morelli A, et al (2010). Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl, 33, 475-88.
  12. Halazun KJ, Hardy MA, Rana AA, et al (2009). Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg, 250, 141-51. https://doi.org/10.1097/SLA.0b013e3181a77e59
  13. Izmirli M, Arikan B, Bayazit Y, et al (2011). Associations of polymorphisms in HPC2/ELAC2 and SRD5A2 genes with benign prostate hyperplasia in Turkish men. Asian Pac J Cancer Prev, 12, 731-3.
  14. Kandirali E, Boran C, Serin E, et al (2007). Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology, 70, 743-7. https://doi.org/10.1016/j.urology.2007.06.1102
  15. Karaman H, Karaman A, Erden A, et al (2013). Relationship between colonic polyp type and the neutrophil/ lymphocyte ratio as a biomarker. Asian Pac J Cancer Prev, 14, 3159-61. https://doi.org/10.7314/APJCP.2013.14.5.3159
  16. Karazanashvili G (2008). Editorial comment on: the relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol, 54, 1383-4. https://doi.org/10.1016/j.eururo.2007.11.027
  17. Konwar R, Manchanda PK, Chaudhary P, et al (2010). Glutathione S-transferase (GST) gene variants and risk of benign prostatic hyperplasia: a report in a North Indian population. Asian Pac J Cancer Prev, 11, 1067-72.
  18. Madersbacher S, Marszalek M, Lackner J, et al (2007). The long-term outcome of medical therapy for BPH. Eur Urol, 51, 1522-33. https://doi.org/10.1016/j.eururo.2007.03.034
  19. McVary KT (2006). BPH: epidemiology and comorbidities. Am J Manag Care, 12, S122-8.
  20. Michel MC, Vrydag W (2006). Alpha1-, alpha2- and betaadrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol, 147, 88-119. https://doi.org/10.1038/sj.bjp.0706619
  21. Mishra VC, Allen DJ, Nicolaou C, et al (2007). Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int, 100, 327-31. https://doi.org/10.1111/j.1464-410X.2007.06910.x
  22. Nunez J, Nunez E, Bodi V, et al (2008). Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol, 101, 747-52. https://doi.org/10.1016/j.amjcard.2007.11.004
  23. Ozden C, Ozdal OL, Guzel O, et al (2007). The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. Int Urol Nephrol, 39, 859-63. https://doi.org/10.1007/s11255-006-9125-2
  24. Partin AW, Carter HB, Chan DW, et al (1990). Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol, 143, 747-52.
  25. Roehrborn CG (2008). BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int, 101, 17-21.
  26. Roehrborn CG, Boyle P, Bergner D, et al (1999). Serum prostatespecific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology, 54, 662-9. https://doi.org/10.1016/S0090-4295(99)00232-0
  27. Sebastiano C, Vincenzo F, Tommaso C, et al (2012). Dietary patterns and prostatic diseases. Front Biosci, 4, 195-204.
  28. SpringerBasicRoehrborn CG, Barkin J, Tubaro A, et al (2014). Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int, 113, 623-35. https://doi.org/10.1111/bju.12500
  29. St Sauver JL, Jacobson DJ, McGree ME, et al (2008). Longitudinal association between prostatitis and development of benign prostatic hyperplasia. Urology, 71, 475-9; discussion 9. https://doi.org/10.1016/j.urology.2007.11.155
  30. Tamhane UU, Aneja S, Montgomery D, et al (2008). Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol, 102, 653-7. https://doi.org/10.1016/j.amjcard.2008.05.006
  31. Walsh SR, Cook EJ, Goulder F, et al (2005). Neutrophillymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol, 91, 181-4. https://doi.org/10.1002/jso.20329

Cited by

  1. Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6407
  2. Importance of Neutrophil/Lymphocyte Ratio in Prediction of PSA Recurrence after Radical Prostatectomy vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1813
  3. Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis vol.11, pp.4, 2016, https://doi.org/10.1371/journal.pone.0153981
  4. The effect of Bongardia Chrysogonum on prostate tissue in a rat model of STZ-induced diabetes vol.5, pp.1, 2016, https://doi.org/10.1186/s40064-016-2973-z